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Introduction
Terminal differentiation within the interfollicular epidermis ul-
timately leads to the formation of a functional skin barrier that 
protects organisms from water loss, infections, and various in-
sults. This barrier is continuously renewed throughout the ani-
mal’s postnatal life span as a result of the presence of stem cells 
that are capable of self-renewal and of producing transiently 
amplifying progenitor cells, which subsequently exit the cell 
cycle and embark on a terminal differentiation pathway as they 
migrate toward the skin surface (Fuchs and Raghavan, 2002). 
This process is recapitulated during embryogenesis, when a 
single layer of multipotent surface ectodermal cells develops 
into a stratifi  ed epidermis. Keratins 5 (K5) and 14 (K14), which 
are expressed in the proliferating basal layer of the mature epi-
dermis, are among the earliest epidermal markers that are acti-
vated in the single-layered ectoderm of the embryonic skin 
(Fuchs, 1993; Koster and Roop, 2004). As development pro-
ceeds, the presumptive suprabasal layers arise and express 
 differentiation-specifi  c keratins K1 and K10 in the intermediate 
spinous layers as well as loricrin, a major component of the 
 future  cornifi  ed envelope (Byrne et al., 1994), in the upper gran-
ular layers. Associated with a spatiotemporally ordered change 
of gene expression are morphological transformations and 
  biochemical events culminating in the formation of a barrier at 
the outermost layer of the epidermis that is impermeable after 
embryonic day (E) 17 (Hardman et al., 1998).
Transcriptional regulation is key to a successful epider-
mal development/differentiation program (for review see Dai 
and Segre, 2004). Among transcription factors that control the 
balance between proliferation and differentiation of keratino-
cytes, the c-myc proto-oncoprotein and the inhibitor of differ-
entiation (Id) family of proteins surfaced as positive regulators 
of a cycling and nondifferentiating progenitor state. However, 
little is known about how the expression of these factors is 
regulated in skin. Although existing studies have provided in-
sights into how homeostasis is achieved in mature epidermis, 
few examine the genetic pathways and molecular mechanisms 
that govern the growth and differentiation of stem/progenitor 
cells of the developing epidermis (Gugasyan et al., 2004; 
Okuyama et al., 2004).
ovo is an evolutionally conserved family of genes 
encoding C2H2 zinc fi   nger transcription factors in animals. 
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ranscriptional control plays a key role in regu-
lating epidermal proliferation and differentiation. 
Although ample information has been obtained on 
how epidermal homeostasis is controlled in adult skin, less 
is known about the control of proliferation/differentiation 
of epidermal stem/progenitor cells in the developing 
  embryo. Ovol1, encoding a zinc ﬁ   nger protein homo-
logous to Drosophila melanogaster Ovo, is expressed in 
embryonic epidermal progenitor cells that are transiting 
from proliferation to terminal differentiation. In this study, 
we demonstrate a function for Ovol1 in interfollicular 
  epidermal development. In its absence, developing epi-
dermis fails to properly restrict the proliferative potential 
of progenitor cells, and cultured keratinocytes fail to efﬁ  -
ciently undergo growth arrest in response to extrinsic 
growth-  inhibitory signals. We present molecular evidence 
that c-myc expression is up-regulated in Ovol1-deﬁ  cient 
suprabasal cells and that Ovol1 represses c-myc tran-
scription by directly binding to its promoter. Collectively, 
our ﬁ  ndings indicate that Ovol1 is required for prolifera-
tion exit of committed epidermal progenitor cells and 
identify c-myc as an Ovol1 target.
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Functional studies in Caenorhabditis elegans,  Drosophila 
 melanogaster, and mice suggest that this gene family plays im-
portant roles in the development of epithelial tissues and germ 
cells (Oliver et al., 1987; Mevel-Ninio et al., 1995; Dai et al., 
1998; Johnson et al., 2001; Mackay et al., 2006). Genetic and bio-
chemical studies suggest that at least two members of this gene 
family,   Drosophila ovo and Ovol1, act downstream of the Wnt–
β-catenin–lymphoid enhancer factor/T cell factor signaling 
pathway (Payre et al., 1999; Li et al., 2002). Recently, OVOL1 
was identifi  ed as a downstream target of the TGF-β/BMP7–
Smad4 signaling pathway, a growth-inhibitory pathway in 
keratinocytes (Kowanetz et al., 2004). Therefore, the ovo gene 
family members appear to be important integrators of upstream 
developmental signals and key regulators of epithelial develop-
ment and differentiation.
Ovol1, the fi  rst mouse ovo that was functionally charac-
terized, is expressed in multiple somatic epithelial tissues, in-
cluding skin (hair follicles and interfollicular epidermis) and 
kidney, as well as in the male germinal epithelium (Dai et al., 
1998). Ovol1-defi  cient mice showed ruffl  ed hairs, cystic kid-
neys, and defective spermatogenesis (Dai et al., 1998). In this 
study, we describe a functional requirement for Ovol1 in epider-
mal development. Specifi  cally, we show that Ovol1 is required 
to restrict the proliferation potential of embryonic epidermal 
progenitor cells in vivo and in vitro. We also present molec-
ular evidence indicating that Ovol1 represses the expression of 
c-myc by direct binding to its promoter, providing a possible 
mechanism by which Ovol1 regulates the proliferation arrest of 
developing epidermal cells.
Results
The K1-positive layers containing 
progenitor cells are expanded 
in the developing Ovol1
−/− epidermis
The initial characterization of Ovol1-defi  cient mice was per-
formed in a 129Sv (129) × C57BL/6 (B6) mixed (50:50) 
  genetic background (Dai et al., 1998). Upon close examination, 
we noticed that the epidermis of these mutant animals was often 
slightly thicker than that of the wild type (unpublished data). 
Because a “pure” B6 strain background can sometimes enhance 
the phenotypic manifestation of a particular mutation (  McGowan 
et al., 2002), we transferred the Ovol1 mutant allele into a B6 
strain background and analyzed the skin morphology of off-
spring from Ovol1
+/− intercrosses. We note that previously de-
scribed phenotypes, including ruffl  ed hairs and cystic kidneys, 
persisted in this new background and that a subset of the Ovol1-
defi  cient pups died perinatally, with the surviving ones exhibit-
ing fl  aky skin (unpublished data).
During normal epidermal development, presumptive su-
prabasal cells appear at ~E15.5 and are morphologically dis-
tinct from the underlying presumptive basal cells (Fig. 1 A). 
Different from those in mature skin, these developing supra-
basal cells express differentiation marker K1 but retain their 
proliferative potential for another 2–3 d (see below; Byrne et al., 
1994; Okuyama et al., 2004) and are, therefore, embryonic epi-
dermal progenitor cells. Although stratifi   cation occurred in 
Ovol1
−/− epidermis at E15.5, the morphological distinction 
  between the presumptive suprabasal and basal layers was not 
apparent in many areas (Fig. 1 B), and more mitotic fi  gures 
were seen than the wild type (Fig. 1 B, arrow; also see below). 
By E16.5, the Ovol1
−/− epidermis, where a morphological strat-
ifi  cation had now become obvious, was considerably thicker than 
the controls, resembling acanthosis described in human patients 
(Fig. 1 D). This defect was not caused by a transient delay in 
development, as it was also observed at later stages (Fig. 1, E–H). 
Furthermore, there was impaired enucleation, fl  attening, and 
compaction of the developing granular cells in mutant epider-
mis (Fig. 1, D, F, and H), suggesting subtle, late differentiation 
defects. No histological defects were apparent in the Ovol1
+/− 
epidermis at all stages examined (unpublished data).
To investigate whether the thickening of Ovol1
−/− mutant 
epidermis was caused by an expansion of the presumptive basal 
or suprabasal layers, we stained the developing epidermis for 
Figure 1.  Histological abnormalities of the developing Ovol1 mutant skin. White dotted line denotes the basement membrane. Arrow in B indicates a 
  mutant mitotic cell in the presumptive suprabasal layer (S). B, basal layer; SC, stratum cornea; Gr, granular layer; Sp, spinous layer. Bar (A and B), 20 μm; 
(C–H) 30 μm.OVOL1 IN EPIDERMAL DEVELOPMENT • NAIR ET AL. 255
K14, K1, and loricrin. As development proceeded from E15.5 to 
the newborn stage, mutant epidermis acquired the expected spa-
tial arrangement of K14, K1, and loricrin- positive layers (Fig. 2). 
However, subtle abnormalities were seen such that at E15.5, the 
loricrin-positive layer was closer in space to the K14-positive 
basal layer than that in the wild type (Fig. 2, D and F; compare 
with C and E). More importantly, beginning at E16.5, the mu-
tant K1-positive layers were signifi  cantly expanded compared 
with their wild-type counterparts (Fig. 2, H, N, and T). 
A slight expansion of the loricrin-positive layers was also ob-
served (Fig. 2, J, L, P, and V), but this was unlikely caused by a 
general expansion of the presumptive granular layers, as no ex-
pansion was observed for cells that were positive for transglu-
taminase 3 (TG3), another marker for granular cells (Fig. 2, 
Q and R). No consistent expansion of the K14-positive layer was 
observed in the mutant. The mutant defects were not associated 
with any apparent change in the expression of K6 (unpublished 
data), which is generally regarded as a wound-healing keratin 
(Mazzalupo et al., 2003). Collectively, these data demonstrate 
that the K1-positive embryonic progenitor cell population was 
expanded in the absence of Ovol1, which underlies the thicken-
ing of the mutant interfollicular epidermis.
Increased proliferation in the developing 
Ovol1
−/− epidermis
The continued expansion of K1-positive progenitor cells in 
 developing  Ovol1
−/− epidermis led us to wonder whether the 
developmental transition between proliferation and differentia-
tion was affected. As measured by BrdU incorporation, epider-
mal proliferation in control embryos slows down as development 
proceeds (Fig. 3 A, compare E15.5 with E16.5; Okuyama et al., 
2004). In its extreme, very little proliferation was observed on 
the dorsal side of the E16.5 wild-type epidermis (Fig. 3 B), 
which is consistent with the fact that the barrier fi  rst forms in 
this region (Hardman et al., 1998). In the mutant, an increase in 
the number of BrdU-positive cells was already evident at E15.5 
(Fig. 3 A and not depicted). By E16.5, mutant epidermis still 
  retained a considerable level of proliferation both dorsally and 
ventrally (Fig. 3 A), with the difference between wild type and 
mutant most prominent in the suprabasal compartment of the 
dorsal region (Fig. 3 C; compare with B). Using an antibody 
that detects phosphorylated histone H3 (H3-P), a marker for 
cells in mitosis (Gurley et al., 1978), we observed a higher aver-
age mitotic index in the mutant than the wild type, particularly 
at later developmental stages (Fig. 3 D and not depicted). 
In keeping with these in vivo fi  ndings, the initial plating of com-
parable numbers of primary keratinocytes isolated from new-
born pups consistently yielded more attached and growing 
keratinocytes for the mutant when compared with their wild-
type control littermates (Fig. 3 E).
Ovol1-deﬁ  cient keratinocytes fail 
to efﬁ  ciently exit proliferation upon induction 
with extrinsic growth-inhibitory signals
A priori, multiple possibilities may account for the observation 
of an increased number of proliferating keratinocytes in mutant 
epidermis. Among these are the precocious activation of a popu-
lation of presumably slow-cycling embryonic epidermal stem 
cells, enhanced rate of proliferation of transit-amplifying pro-
genitor cells, or impaired growth arrest of progenitor cells. Ovol1 
expression was observed in the presumptive suprabasal layers 
but was barely detectable in the presumptive basal layer (Dai 
et al., 1998) where embryonic epidermal stem cells presumably 
reside, making the fi  rst possibility highly unlikely. FACS analysis 
Figure 2.  Expansion of the K1-positive progenitor layers in the developing Ovol1
−/− epidermis. Results of immunoﬂ  uorescence staining of skin from 
wild-type (A, C, E, G, I, K, M, O, Q, S, and U) and Ovol1
−/− (B, D, F, H, J, L, N, P, R, T, and V) mice at E15.5 (A–F), E16.5 (G–L, Q, and R), E17.5 (M–P), 
and newborn (S–V) stages using a FITC-conjugated α-K1 (A, B, G, H, M, N, S, and T) or α-loricrin antibody (green; C–F, I–L, O, P, U, and V) and a rhodamine-
conjugated α-K14 antibody (red) or a FITC-conjugated α-TG3 antibody (green; Q and R). Bar (A–D, G–J, M–P, and S–V), 30 μm; (E, F, K, L, Q, 
and R) 10 μm.JCB • VOLUME 173 • NUMBER 2 • 2006  256
identifi  ed a similar percentage of cells that are positive for α6 
integrin, a marker for basal keratinocytes (Sonnenberg et al., 
1991), in keratinocyte preparations from wild-type and Ovol1-
defi  cient newborn epidermis (unpublished data). Furthermore, 
a growth analysis of actively proliferating keratinocytes of 
  secondary passages in the absence of any growth-inhibitory 
treatment revealed no difference between the wild type and mu-
tant (Fig. 4 A). Together, these results argue against an involve-
ment of Ovol1 in embryonic epidermal stem cell activation and 
in regulating the rate of keratinocyte proliferation itself.
Several treatments have been shown to induce the exit 
of proliferation and possibly terminal differentiation of 
Figure 3.  Increased number of cycling cells in the developing Ovol1 mutant epidermis. (A) Comparison of the number of BrdU-positive cells (average 
number per 1,000-μm distance) in dorsal and ventral epidermis of wild type and mutant at the indicated ages. (B and C) Representative stained sections 
from the dorsal region of wild-type (B) and mutant (C) skin at E16.5. Dotted lines denote the basement membrane. (D) Mitotic index of wild-type and Ovol1-
deﬁ  cient embryonic skin at the indicated ages. The mitotic index was calculated as the ratio of the number of cells in the developing interfollicular 
  epidermis that stained positive for H3-P over the total number of cells as determined by DAPI staining. (E) More attached and growing keratinocytes were 
recovered from newborn Ovol1 mutant epidermis. Bars represent an average of three homozygous mutant pups or two wild-type controls, all from a single 
litter. Similar   results were obtained from additional litters (not depicted). *, P < 0.03 difference from the wild-type counterparts. Error bars represent SEM. 
Bar (B and C), 30 μm.
Figure 4.  Inefﬁ  cient growth arrest of Ovol1-
deﬁ  cient  keratinocytes.  (A) Wild-type and 
  mutant keratinocytes show a comparable pro-
liferation rate. (B and D) BrdU-labeling index 
of keratinocytes cultured in the absence or 
presence of Ca
2+ (B) or TGF-β (D). Error bars 
were calculated from three replicate samples 
of each condition. (C) Relative conﬂ  uency of 
keratinocytes cultured in the absence or pres-
ence of LiCl. Results from WT and mutant off-
spring of a single litter are shown. Similar 
ﬁ   ndings were obtained from multiple litters. 
*, P < 0.02 difference from two independently 
derived wild-type keratinocyte preparations.OVOL1 IN EPIDERMAL DEVELOPMENT • NAIR ET AL. 257
cultured keratinocytes. These include high concentrations of 
Ca
2+ (Hennings et al., 1980), LiCl, which is thought to mimic acti-
vated canonical Wnt signaling by inhibiting GSK3β (Olmeda 
et al., 2003), and TGF-β (Shipley et al., 1986). Therefore, we ex-
amined the ability of Ovol-defi  cient keratinocytes to exit prolif-
eration in response to these reagents. First, wild-type and mutant 
keratinocytes were cultured in the presence of low ( 0.09 mM) 
or high (1.2 mM) Ca
2+, and their BrdU-labeling index was 
  determined. Although a time-dependent decrease in the number 
of BrdU-labeled cells was observed for the wild type upon Ca
2+ 
treatment, the BrdU-labeling index remained high in Ovol1-
 defi  cient keratinocytes even 24 h after Ca
2+ addition (Fig. 4 B). 
Second, LiCl, which induced effi  cient growth arrest of wild-type 
keratinocytes (as indicated by the <10% confl  uency of treated 
plates at the time when untreated replicate plates reached 100% 
confl  uency), failed to do so with the mutant cells (Fig. 4 C). 
Finally, a concentration of TGF-β that caused a signifi  cant re-
duction in the BrdU-labeling index in wild-type cells failed to 
cause Ovol1-defi  cient keratinocytes to stop cycling (Fig. 4 D). 
Collectively, our results indicate that the loss of Ovol1 renders 
the proliferating keratinocytes in culture less sensitive to extrinsic 
growth-inhibitory signals.
c-myc expression in the presumptive 
suprabasal layers of Ovol1-deﬁ  cient 
epidermis was not properly down-regulated
The inability of Ovol1-defi  cient epidermal progenitor cells to 
exit proliferation implies that Ovol1 normally functions in the 
developing epidermis to ensure the growth arrest of these cells. 
As it has been shown that a down-regulation of c-myc expres-
sion in suprabasal cells is important to maintain a postmitotic 
status (Pelengaris et al., 1999; Waikel et al., 1999), we hypo-
thesized that Ovol1 may function by down-regulating c-myc 
  expression. To test this hypothesis, we performed in situ hybrid-
ization experiments on developing epidermis using a c-myc 
cRNA probe. Although hybridization signals were observed in 
all layers of the interfollicular epidermis of both wild-type and 
Ovol1-defi  cient E15.5 embryos, a slight reduction in signal in-
tensity was often apparent in the newly formed presumptive su-
prabasal layers of the wild type but not mutant (Fig. 5, A and B). 
As development proceeded to E18.5, the intensity of c-myc 
  hybridization signals became weaker overall, with only a few 
scattered basal cells showing detectable expression (Fig. 5 C). 
In the mutant, however, many suprabasal cells showed clearly 
detectable hybridization signals, including those that are close 
to the skin surface (Fig. 5 D, arrows). The number of c-myc–
  expressing basal cells was also signifi  cantly higher. Addition-
ally, our analysis of c-myc protein expression in embryonic skin 
revealed differences between the wild-type and mutant epider-
mis that are similar to those observed at the RNA level (Fig. 5, 
E–H). Of particular note is that although no staining was ob-
served in the wild-type suprabasal cells at E18.5, those in the 
mutant epidermis retained strong nucleolar signals that are 
characteristic of the c-myc protein (Fig. 5 H, arrowheads; Arabi 
et al., 2005; Sanders and Gruppuso, 2005). To better quantify 
the difference in c-myc expression, we performed Northern blot 
Figure 5.  c-myc expression is up-regulated in developing suprabasal layers of the Ovol1-deﬁ  cient epidermis. Results of situ hybridization (A–D) and 
  immunostaining (E–H) of wild-type (A, C, E, and G) and mutant (B, D, F, and H) embryonic skin using a c-myc cRNA probe and a mouse anti–c-myc anti-
body, respectively. Note that at E18.5, c-myc protein is cytoplasmic in the basal layer, and at least some c-myc transcripts appeared nuclear, which proba-
bly stems from the reported delicate control of subcellular localizations of c-myc gene products to tailor the needs of cell cycle control in these cells (Vriz 
et al., 1992; Bond and Wold, 1993). Dotted lines denote the basement membrane. Arrows and arrowheads indicate mutant suprabasal cells expressing 
c-myc mRNA and protein, respectively. (I) Results of Northern blot analysis of E16.5 wild-type and mutant skin. Each blot was stripped and reprobed with 
a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe. (J and K) Real-time PCR analysis of c-myc transcript levels (J) and reporter assays of c-myc 
promoter activity (K) in wild-type and mutant keratinocytes 24 h after Ca
2+ induction. Average values obtained on cells from three mutant and three con-
trol animals are shown. Luciferase activities were normalized for transfection efﬁ  ciency by using a β-actin promoter driving lacZ as an internal control. 
*, P < 0.03 difference from the wild type. Error bars represent SEM. Bar, 20 μm.JCB • VOLUME 173 • NUMBER 2 • 2006  258
analysis on RNA isolated from E16.5 embryonic skin and ob-
served an  1.7-fold higher level of c-myc transcripts in the mutant 
than the wild type (Fig. 5 I). The expression of Id2, which was pre-
viously shown to be a target of c-myc transcriptional activation in 
skin and a target of Ovol1 transcriptional repression in the testis 
(Lasorella et al., 2000; Murphy et al., 2004; Li et al., 2005a), was 
also up-regulated by  1.5-fold in Ovol1-defi  cient skin (Fig. 5 I).
Although a failure to down-regulate c-myc expression in the 
mutant presumptive suprabasal cells could be a primary conse-
quence of the loss of Ovol1 as it is expressed in these cells, the in-
crease of c-myc expression in basal cells that normally do not 
express an appreciable amount of Ovol1 is curious and may be 
a secondary effect. To begin to distinguish between primary and 
secondary changes, we isolated primary keratinocytes from wild-
type and mutant newborns and performed real-time PCR analysis 
to determine the level of endogenous c-myc transcripts in these 
isolated epidermal cells. No statistically signifi  cant difference was 
observed between wild-type and mutant keratinocytes that were 
basal-like when they were cultured under undifferentiating condi-
tions (unpublished data). However, after these cells were treated 
with differentiation-inducing Ca
2+, a signifi  cantly higher level of 
c-myc transcripts was detected in the mutant preparations (Fig. 5 J). 
To determine whether the increase in the c-myc transcript level 
was a result of increased transcription, we cloned a 2.3-kb human 
c-myc promoter fragment upstream of a luciferase reporter gene 
(see Fig. 7 A) and transfected the reporter construct into wild-type 
and mutant keratinocytes. Again, Ca
2+-treated mutant keratino-
cytes allowed higher promoter activity than the wild type, whereas 
no difference was observed in untreated cells (Fig. 5 K and not 
depicted). Collectively, our results strongly suggest that Ovol1 is 
required to down-regulate c-myc transcription during epidermal 
development in the growth-restricted suprabasal cells.
Biochemical evidence that Ovol1 represses 
c-myc transcription by direct binding 
to the c-myc promoter
Does Ovol1 protein directly repress c-myc transcription, or are 
intermediate factors involved? To address this issue, we turned 
to study the nucleotide sequence determinants of Ovol1–DNA 
interaction. Previously, we showed that Ovol1 is able to bind to 
a Drosophila Ovo consensus sequence (Li et al., 2002). Since 
then, we have identifi  ed mouse genomic sequences to which 
Ovol1 binds in vitro and arrived at a putative consensus motif, 
CCGTTA (unpublished data). Although single nucleotide muta-
tion in this motif (C1C2G3T4T5A6: C1→A, C2→T, G3→T, T4→G, 
T5→G, or A6→C) resulted in diminished Ovol1 binding (Fig. 6, 
A and B), deletion or scramble of this hexamer motif totally 
abolished binding (Fig. 6, A and C). On the other hand, the in-
sertion of a CCGTTA sequence into an oligonucleotide to which 
Ovol1 does not bind (nso; Li et al., 2002) was able to confer 
binding (Fig. 6, A and D). Together, these results indicate that a 
CCGTTA sequence is necessary and suffi  cient to confer high-
affi  nity Ovol1–DNA interaction in vitro.
We next examined the sequences of gene-regulatory re-
gions of both mouse and human c-myc genes and found that 
both contained a single CCGTTA motif, the position of which is 
also conserved (Fig. 7 A). In gel shift assays, recombinant 
Ovol1 bound to oligonucleotide c-myc, which contains human 
c-myc sequences including the CCGTTA motif (Fig. 7 B, lanes 
2–6). The identity of the Ovol1–DNA complex was confi  rmed 
by the observation of a band supershift when anti-Ovol1 anti-
body was added to the binding reaction (Fig. 7 B, lane 7), and 
binding was abolished when the CCGTTA sequence was mu-
tated (Fig. 7 B, lanes 9–13). Together, these results identify 
a bone fi  de Ovol1-binding site in the c-myc promoter.
We next used chromatin immunoprecipitation (ChIP) as-
says to determine whether Ovol1 was engaged at the endogenous 
human c-myc promoter (see Materials and methods). The anti-
Ovol1 antibody-precipitated DNA was subject to PCR ampli-
fi  cation with fi  ve pairs of primers spanning fi  ve long sequence 
blocks of the c-myc promoter that are conserved between 
mice and humans (Fig. 7 A). Ovol1 occupancy was detected 
with primer pairs Cm-2, Cm-3, Cm-4, and Cm-5 but not with 
Cm-1 (Fig. 7 C). No signal was observed when normal rabbit 
IgG was used for precipitation, showing the specifi  city of 
this assay. Quantitative analysis revealed two peaks of Ovol1 
Figure 6.  The CCGTTA hexamer is necessary 
and sufﬁ   cient for Ovol1 recognition. (A) Se-
quence of oligonucleotides used in EMSA 
  assays. (B) Competition assays were per-
formed with Ovol1D (an oligonucleotide con-
taining a high-afﬁ   nity Ovol1-binding site) as 
the labeled probe and Ovol1D or oligonucle-
otides with indicated point mutations within the 
CCGTTA sequence as unlabeled competitors 
(present at a 100-fold excess). (C) EMSA as-
says using the Ovol1D oligonucleotide or its 
mutant derivatives showing that the CCGTTA 
hexamer sequence was necessary for Ovol1–
DNA interaction. (D) EMSA assays using the 
nso oligonucleotide or its derivative showing 
that the CCGTTA hexamer sequence was sufﬁ  -
cient for Ovol1–DNA interaction. Ovals and 
arrowheads indicate the positions of Ovol1–
DNA complexes and free probes, respectively.OVOL1 IN EPIDERMAL DEVELOPMENT • NAIR ET AL. 259
binding: one encompassed the CCGTTA sequence (primer set 
Cm-2), and the other was located in the proximal promoter re-
gion, which overlaps the sixth conserved block (primer set Cm-5; 
Fig. 7, A and D). These results indicate that Ovol1 physically as-
sociates with the endogenous c-myc promoter at the predicted 
distal site inside cells; however, they also reveal additional sites 
in the proximal promoter region that are occupied by Ovol1. 
We performed gel shift experiments on overlapping fragments en-
compassing this entire proximal region but observed no evidence 
of binding of recombinant Ovol1 to any fragment in this in vitro 
assay (unpublished data), raising the possibility that an alterna-
tive mechanism (e.g., assistance from auxiliary factors) exists 
in vivo to bring Ovol1 protein to this region (see Discussion).
Having established that Ovol1 binds to the c-myc pro-
moter in vitro and in cells, we next used reporter assays to in-
vestigate whether Ovol1 directly represses c-myc transcription. 
The 2.3-kb human c-myc promoter fragment was able to direct 
active transcription in both UG1 mouse keratinocytes (Dai et al., 
1998) and 293T cells (Fig. 7, A, E, and F). Cotransfection of an 
Ovol1 expression vector repressed reporter expression in both 
culture systems in a dosage-dependent manner (Fig. 7, E and F). 
To confi  rm that the observed repression is an Ovol1 protein–
  dependent event, we created the chimeric protein VP16-Ovol1 
in which Ovol1 was fused to a strong, well-characterized trans-
activation domain from VP16 with the assumption that this 
activation domain might override the intrinsic transcriptional 
Figure 7.  Ovol1 represses c-myc transcription by associating with two regions in its promoter. (A) Diagram of the human c-myc promoter in plasmid 2.3P 
(pGL3–c-myc) and in the deletion constructs 1.6P, 1.2P, and 0.1P. Transcription start sites are indicated as P1 and P2. Heavy bars indicate regions with sig-
niﬁ  cant similarity to the mouse c-myc gene. (B) EMSA and supershift assays showing binding of recombinant Ovol1 to a CCGTTA-containing sequence in 
the c-myc promoter. Black oval and arrowhead indicate the positions of Ovol1–DNA complexes and free probes, respectively. Lanes 1–6: c-myc oligonucle-
otide in the absence (lane 1) and presence of increasing concentrations of the recombinant Ovol1 protein (lanes 2–6). Lane 7: Ovol1 binding to c-myc oli-
gonucleotide in the presence of an anti-Ovol1 antibody. Lanes 8–13: a mutant version of c-myc oligonucleotide in which the CCGTTA sequence is replaced 
by ATGCGC with (lanes 9–13) and without (lane 8) recombinant Ovol1. (C) Results of PCR ampliﬁ  cations using primer sets Cm-1 (1), Cm-2 (2), Cm-3 (3), 
Cm-4 (4), and Cm-5 (5; see A for locations of regions ampliﬁ  ed by these primers). I, input; +, with anti-Ovol1 antibody; −, with IgG control. (D) Quantita-
tive analysis of Ovol1 occupancy at various positions (see 1–5 in C) of the human c-myc promoter. (E and F) Dosage-dependent repression of c-myc pro-
moter luciferase reporter expression by Ovol1 in UG1 (E) and 293T (F) cells. The triangles indicate increasing concentrations (0.01, 0.02, and 0.05 μg) 
of the Ovol1-expressing vector. (G) Dosage-dependent activation of reporter expression by VP16-Ovol1. (H) Repression of c-myc 2.3P depends on the pres-
ence of the ﬁ  rst 15 amino acids of Ovol1 and the DNA-binding zinc ﬁ  nger domain. Expression levels of the mutant proteins were comparable with that of 
the wild type, as shown by Western blot analysis (not depicted). (I) Deletion (1.2P) and point mutations (mut-1.6P) of the CCGTTA Ovol1-binding site led 
to a signiﬁ  cant reduction in repression by Ovol1. (J) Residual repression of a minimum c-myc promoter fragment (0.1P) by Ovol1. Each bar represents the 
average of triplicate samples in a single experiment, and the results are representative of several independent experiments. Error bars represent SEM. 
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regulatory activity of Ovol1 and result in an activator. Indeed, 
VP16-Ovol1 activated the c-myc promoter in a dosage-
dependent manner (Fig. 7 G). In contrast, the VP16 domain 
alone had no effect at all concentrations tested, indicating that 
the fusion protein was recruited to the c-myc promoter by its 
Ovol1 moiety. The specifi  city of the effect of Ovol1 was further 
demonstrated by the fi   nding that a truncated Ovol1 protein 
(d15-Ovol1) lacking the fi  rst 15 amino acids at the NH2 termi-
nus, which resembles the known repression domain SNAG 
(Nieto, 2002), failed to effi  ciently repress the c-myc promoter 
activity (Fig. 7 H).
To determine whether repression depends on the DNA 
binding ability of Ovol1, we generated a construct expressing 
a mutant form of the Ovol1 protein in which the cysteine amino 
acids in the fi  rst three zinc fi  ngers were replaced by alanine 
(ZnFC2A). This mutant protein, which is no longer able to bind 
DNA (not depicted), failed to repress the c-myc promoter (Fig. 
7 H). To further explore the dependence of repression on DNA 
binding, we generated mutant promoters in which upstream 
sequences were deleted or mutated. Although the deletion of 
sequences from –2.3 to –1.6 kb had no effect (not depicted), 
a partial release of repression was observed when a 373-bp 
sequence containing the CCGTTA site was removed (Fig. 7, 
A and I). Moreover, replacing the CCGTTA motif with a non-
Ovol1 binding sequence, ATGCGC, led to a similar reduction in 
repression by Ovol1 (promoter construct mut-1.6P in Fig. 7 I), 
confi  rming that this site is indeed required for mediating Ovol1 
repression. This said, considerable residual repression was still 
observed, implicating the contribution of other cis-elements. 
Analysis of additional deletion constructs mapped the minimum 
Ovol1 responsive region to within the smallest promoter frag-
ment tested (the 0.1P construct; Fig. 7, A and J; and not depicted). 
The position of this region coincides with that of the proximal 
Ovol1-binding site identifi  ed by the aforementioned ChIP assays, 
implying that Ovol1 repressed this minimum promoter by 
binding to it. Collectively, our data suggest that Ovol1 represses 
c-myc transcription by binding to its promoter.
Aberrant loricrin expression 
in Ovol1-deﬁ  cient skin
The apparent expansion of loricrin-positive layers in Ovol1-
 defi  cient skin in the absence of any concomitant expansion of 
the TG3-positive layers raises the possibility that loricrin ex-
pression is aberrantly activated in intermediate suprabasal cells 
when Ovol1 is ablated. We next used Western blot analysis to 
determine loricrin protein levels in wild-type and Ovol1 mutant 
skin from different developmental stages. Although mutant skin 
started out expressing a slightly lower level of loricrin protein 
(75% of that in wild type at E15.5 after normalization against 
actin levels), possibly because of a transient delay in the 
  proliferation–differentiation switch, it produced a much higher 
level of the protein at later stages (approximately fourfold 
higher than the wild type at E18.5; Fig. 8 A). Using semiquanti-
tative RT-PCR, we detected a twofold increase in loricrin RNA 
levels in the mutant skin taken from E16.5 embryos (Fig. 8 B), 
confirming that increased loricrin expression occurred at 
a transcriptional level.
To better understand the effect of Ovol1 ablation on lor-
icrin expression, we examined the effect of Ovol1 protein on 
loricrin promoter activity using reporter assays. We cloned 
a mouse loricrin promoter fragment (DiSepio et al., 1995) 
  upstream of a luciferase reporter gene and found that this frag-
ment directed active transcription in both UG1 and 293T cells 
(Fig. 8 C). This observation is consistent with previous fi  ndings 
that a core loricrin promoter fragment directs expression in not 
only granular cells but also basal and spinous cells of transgenic 
mice (DiSepio et al., 1995). Cotransfection of an Ovol1 ex-
pression vector repressed loricrin promoter activity in both cell 
Figure 8.  Up-regulated loricrin expression in Ovol1-deﬁ  cient skin and repression of loricrin promoter activity by Ovol1 in reporter assays. (A) Western 
blot analysis of loricrin protein levels in wild-type and mutant skin. β-actin was used as a loading control. (B) RT-PCR analysis showing an up-regulation of 
loricrin transcripts in E16.5 Ovol1
−/− mutant skin. (C) Ovol1 represses loricrin promoter–luciferase reporter gene expression. (D) VP16-Ovol1 activated 
  reporter expression in a dosage-dependent manner. Data treatment and presentation are as described in Fig. 6. Error bars represent SEM.OVOL1 IN EPIDERMAL DEVELOPMENT • NAIR ET AL. 261
  systems (Fig. 8 C). However, at high Ovol1 concentrations, we 
often observed a release of repression, which was likely a result 
of “squelching” caused by Ovol1 binding to specifi  c  trans-
  acting factors that might be limiting in these cells. To confi  rm 
that the observed regulation is an Ovol1 protein–dependent 
event, we tested VP16-Ovol1, assuming that this chimeric acti-
vator would likely bypass the requirement for those limiting 
factors needed for repression. Indeed, VP16-Ovol1 activated 
  loricrin promoter–luciferase reporter expression in a clearly 
dosage-  dependent manner, whereas the VP16 activation domain 
alone had no signifi  cant effect (Fig. 8 D). A CCGTTA sequence 
was found in the loricrin promoter; however, this site is very 
close to the transcription start so that its mutation abolished 
  promoter activity, preventing us from examining the DNA site 
  dependence of Ovol1 repression (unpublished data). Nonethe-
less, our data demonstrate that Ovol1 is capable of repressing 
loricrin expression in a cell-autonomous manner.
Discussion
Ovol1 and the proliferation potential 
of embryonic epidermal progenitor cells
Our studies identifi  ed a novel function of Ovol1 in epidermal 
development. The expansion of K1-positive layers and increase 
in the number of actively proliferating cells in the developing 
epidermis of Ovol1-defi  cient mice are consistent with a hyper-
proliferative defect. A priori, hyperproliferation may occur as 
a primary cell-autonomous consequence of Ovol1 ablation in 
the proliferative compartment or as a secondary consequence 
of abnormal terminal differentiation and/or barrier defects, as 
frequently observed in the study of adult epidermis. Several 
lines of fi  ndings support the former possibility. First, increased 
proliferation was already evident at E15.5, which is before 
late-terminal differentiation events occur and a barrier forms. 
Although a transient delay in barrier acquisition was observed 
in Ovol1-defi  cient embryos, all were fully impermeable to dye 
penetration at the age of E18.5–newborn (unpublished data), 
suggesting that barrier development is largely normal (Hardman 
et al., 1998). Late-differentiation defects and delayed bar-
rier formation were also observed in loricrin knockout mice, 
yet loricrin-defi  cient epidermis is not acanthotic (Koch et al., 
2000), indicating that these defects are not suffi  cient to trigger 
a compensatory hyperproliferative response in the embryo. 
Second, the expression of K6, which is typically up-regulated in 
repair-associated hyperproliferation (Mazzalupo et al., 2003), 
was not affected in the developing Ovol1 mutant epidermis. 
Finally, the most direct evidence came from our observation that 
keratinocytes isolated from mutant animals could not be effi  ciently 
induced to exit the cell cycle in response to extrinsic growth-
  inhibitory signals such as Ca
2+, LiCl, and TGF-β. As these cells 
were cultured independently of feeders, this analysis allowed 
a direct assessment of the intrinsic proliferative capacity of the 
mutant epidermal cells. Based on these results and the onset 
of Ovol1 expression in early presumptive suprabasal cells (Fig. 
9 A), we propose that Ovol1 is required for the growth arrest 
of embryonic progenitor cells during epidermal development 
(Fig. 9 B). It is worth mentioning that similar to the epidermis, 
Ovol1-defi  cient male germ cells were sluggish in exiting mito-
sis (Li et al., 2005a). Therefore, Ovol1 might play a general role 
in down-regulating the proliferation of developmental progeni-
tor cells in tissues that require its function.
While this study was in revision, Lechler and Fuchs (2005) 
published that epidermal stratifi  cation during mid–late gesta-
tion, where p63 is critically involved (Mills et al., 1999; Koster 
et al., 2004), entails asymmetric divisions of the ectodermal 
cells, yielding a basal cell and a suprabasal cell with a short-
lived proliferation potential. Ovol1 expression is activated 
immediately upon stratifi   cation in these transit-amplifying 
suprabasal layers (Dai et al., 1998). Although stratifi  cation oc-
curred in the absence of Ovol1, the newly formed mutant supra-
basal cells appeared different in size and shape from their 
wild-type counterparts despite their ability to express K1 (Figs. 
1 and 2). Is it possible that Ovol1 is an intrinsic molecular 
“clock” built into the suprabasal daughter cell that somehow 
makes it different from its long-lived parent and its postmitotic 
successors in terms of proliferation potential, so that in its ab-
sence, this daughter cell is improperly programmed upon strati-
fi  cation and, therefore, carries out just a few more rounds of 
proliferation than it should? What signals lie upstream of Ovol1? 
Existing evidence tentatively places Ovol1 downstream of Wnt 
Figure 9.  Working model of the role of Ovol1 in 
  epidermal development. The location of Ovol1 ex-
pression in developing epidermis with respect to dif-
ferentiation markers is indicated in A. PB, presumptive 
basal layer; PS, presumptive spinous layer; PG, presump-
tive granular layer. The model of the role of Ovol1 is 
shown in B.JCB • VOLUME 173 • NUMBER 2 • 2006  262
as well as TGF-β1/BMP signaling. The suprabasal hyperprolif-
erative phenotype of Ovol1-defi  cient epidermis is similar to that 
observed in Ikkα-defi  cient mice (Hu et al., 1999; Takeda et al., 
1999) and in mice with the repeated epilation (Er) mutation, 
which is a mutation in 14-3-3σ (Li et al., 2005b). However, 
  loricrin expression is completely blocked in the absence of Ikkα 
or in Er mice but only slightly delayed in the absence of Ovol1, 
suggesting that Ovol1 lies downstream of Ikkα and 14-3-3σ in 
the epidermal differentiation process. It is tempting to speculate 
that Ovol1 might be a key integrator of upstream developmental 
signals/molecular triggers like Wnt, TGF-β/BMP, and Ikkα in 
negative growth regulation during embryonic development. As 
little is known about the signaling and transcriptional network 
regulating the proliferation to differentiation transition during 
epidermal development, our elucidation of an in vivo role for 
Ovol1, a target of well-known signaling pathways, offers inter-
esting new angles to understand these cellular and develop-
mental processes.
The molecular mechanism of Ovol1’s 
function in growth arrest
How does Ovol1 down-regulate the proliferation of embryonic 
epidermal progenitor cells? We probed this important question 
by characterizing the DNA binding specifi  city of the protein 
and looking for possible downstream targets. These studies led 
us to the discovery of c-myc as a direct Ovol1 target. Repres-
sion of the c-myc promoter by Ovol1 in reporter assays as well 
as results of ChIP assays detecting a physical association of 
Ovol1 to the endogenous c-myc promoter in its chromatin con-
text indicate that Ovol1 can directly repress c-myc expression. 
This provides at least one possible molecular mechanism 
by which Ovol1 down-regulates proliferation (Fig. 9 B). The 
up-regulation of c-myc expression in Ovol1-defi  cient supra-
basal cells as well as the phenotypic parallel, namely abnormal 
suprabasal proliferation, between Ovol1-defi   cient mice and 
transgenic mice that overexpress c-myc under the suprabasal-
expressing involucrin or loricrin promoter provide in vivo vali-
dation for this model (Pelengaris et al., 1999; Waikel et al., 
1999; Flores et al., 2004).
The underlying mechanism by which Ovol1 is recruited to 
the c-myc promoter appears complex, as we found two regions 
in the promoter that mediate Ovol1 repression and are bound by 
Ovol1 inside cells, yet only one region contains a detectable in 
vitro binding site. Alternative mechanisms, such as the use of 
DNA-binding partners to enhance binding affi  nity/specifi  city or 
via protein–protein interactions (Massague, 2000), likely exist 
as additional means to recruit Ovol1 to its target promoters in 
vivo. Future work is necessary to systematically explore these 
“hidden” cis-elements to fully understand the biochemical mech-
anism of Ovol1 repression.
It is unlikely that c-myc serves as the only Ovol1 target to 
mediate its negative effect on proliferation. Our previous study 
on the role of Ovol1 in male germ cell differentiation identifi  ed 
Id2 as a direct target of the Ovol1 protein (Li et al., 2005a). The 
observation of increased Id2 expression in Ovol1-defi  cient skin 
suggests that Id2 is also repressed by Ovol1 during epidermal 
development, probably both directly by Ovol1 binding to its 
promoter and indirectly because of increased c-myc gene pro-
ducts, as it has been shown that c-myc induces Id2 expression in 
epidermis (Murphy et al., 2004). As both c-myc and Id2 have 
been implicated in tumorigenesis, these fi  ndings also raise the 
possibility that Ovol1 might play a negative role in malignant 
growth. Although the biological function of ovo genes has been 
studied in various organisms, our study reports the fi  rst identifi  -
cation of candidate molecular targets of ovo, namely c-myc and 
Id2, two key positive regulators of proliferation and negative 
regulators of differentiation, that bear relevance to the cellular 
process that they regulate.
Ovol1 and terminal differentiation 
in the developing epidermis
Is Ovol1 also required for terminal differentiation itself in the 
developing epidermis? The expression of differentiation mark-
ers such as K1, loricrin, and TG3 is detected in the Ovol1 
  mutant, indicating that the epidermis is able to execute a largely 
normal terminal differentiation process in the absence of a func-
tional Ovol1 gene. This said, morphological defects in the 
  granular layers as well as a premature activation of loricrin 
  expression in the intermediate layers were observed. These ab-
normalities are subtle and are apparently not translated into 
  severe functional impairment of the skin, as mutant embryos 
acquire a functional barrier with only a transient delay of  1 d 
or so (unpublished data).
The premature activation of loricrin expression in the 
 absence  of  Ovol1 together with the observation that Ovol1 re-
presses the activity of the loricrin promoter in reporter assays 
led us to propose that Ovol1 might normally act to transiently 
repress loricrin expression in late presumptive spinous layers 
(Fig. 9). As the developing epidermis switches from a growing 
to a differentiating mode during late embryogenesis, a proposed 
involvement of Ovol1 in preventing premature terminal differ-
entiation events at the critical cross-road might be important to 
ensure an orderly progression of the terminal differentiation-
  associated gene expression program. Alternatively, the up-
  regulated loricrin expression in Ovol1-defi  cient epidermis from 
E16.5 onward might be a secondary consequence of the muta-
tion. Clearly, future studies are necessary to distinguish between 
these possibilities.
Materials and methods
Mouse breeding
Ovol1
+/− mice in a 129 × B6 mixed genetic background were back-
crossed with B6 mice for 8–10 sequential generations, which, under no se-
lection, is expected to generate a genetic background that is  99.9% B6. 
Ovol1
+/− mice with an enriched B6 genetic background were then inter-
crossed to produce homozygous mutant progeny for study.
Histology and immunoﬂ  uorescence
Embryos or backskin samples were ﬁ  xed in Bouin’s ﬁ  xative for 12–24 h at 
room temperature or in 4% PFA overnight at 4°C. 5 μm of parafﬁ  n or 5 μm 
of frozen sections were prepared and stained with hematoxylin and eosin 
or the appropriate polyclonal antibodies as described previously (Dai 
et al., 1998): rabbit K1 (1:500; Covance), rabbit K14 (1:1,000; 
Covance), guinea pig K14 (1:50; a gift from D. Roop, Baylor College of 
Medicine, Houston, TX; Waikel et al., 2001), rabbit loricrin (1:50; Mehrel 
et al., 1990), rabbit TG3 (1:100; a gift from L. Milstone, Yale University 
School of Medicine, New Haven, CT), rabbit K6 (1:200; a gift from OVOL1 IN EPIDERMAL DEVELOPMENT • NAIR ET AL. 263
P. Coulombe, Johns Hopkins University School of Medicine, Baltimore, 
MD; Mazzalupo et al., 2003), mouse c-myc (1:500; Abcam), and rabbit 
phosphorylated histone-H3 (1:1,000; Upstate Biotechnology). Images 
were acquired with a microscope (Eclipse E600; Nikon).
BrdU labeling
Pregnant females were injected intraperitoneally with BrdU (Sigma-Aldrich) 
at a dosage of 50 μg/g of body weight, killed 2 h after injection, and em-
bryos were dissected and ﬁ  xed in 4% PFA. Embryos were then washed in 
PBS and frozen in optimal cutting temperature (Tissue-Tek). Frozen sections 
were treated with 50% formamide in 2× SSC at 65°C for 2 h followed by 
two brief 5-min rinses in 2× SSC and were incubated in 2N HCl at 37°C 
for 30 min. Samples were neutralized by incubation in 0.1M boric acid, 
pH 8.5, for 10 min, rinsed brieﬂ  y in PBS, and endogenous peroxidase was 
quenched by incubating in freshly prepared 3% H2O2 for 15 min. After 
three 5-min washes in PBS, samples were subjected to immunohistochemical 
analysis using a mouse monoclonal anti-BrdU antibody (Roche) according 
to the manufacturer’s instructions.
Culture and analysis of primary keratinocytes
Keratinocytes were isolated from newborn backskin of mutant and wild-
type littermates using an established protocol (Caldelari et al., 2000). 
About 4–6 × 10
6 cells were recovered from each mouse and were plated 
at comparable cell densities (passage 0). The total number of attached 
cells obtained from each mouse was counted after 5 d of the initial plating 
and subsequently normalized against the total number of cells plated. For 
growth curve analysis, 3 × 10
5 cells of passage 1 were plated in replicate 
wells of six-well plates, and the total number of cells at 2, 3, and 4 d after 
plating were counted.
For determination of the BrdU-labeling index in culture, wild-type 
and mutant keratinocytes were seeded in chamber slides precoated with 
collagen (36.9 μg/ml in PBS) and ﬁ  bronectin (5 μg/ml in PBS) and were 
allowed to grow overnight. CaCl2 (ﬁ  nal concentration of 1.2 mM), LiCl 
(ﬁ  nal concentration of 20 mM), or TGF-β (ﬁ  nal concentration of 1 ng/ml; 
Research Diagnostic) was added to the culture, and samples were ﬁ  xed at 
various time points after the addition as indicated in the ﬁ  gures. BrdU was 
added 1 h before ﬁ  xation at a ﬁ  nal concentration of 10 μM, and ﬁ  xation 
was in 100% methanol at −20°C for 10 min followed by three 5-min 
washes with 1× PBS. Keratinocytes were subsequently treated with 1N 
HCl for 30 min at 37°C followed by brief washes in PBS and were subject 
to immunohistochemical analysis as described in the previous section.
EMSA
Electrophoretic mobility shift assays (EMSAs) were performed using differ-
ent amounts of partially puriﬁ  ed recombinant His6-Ovol1 (ﬁ  nal concentra-
tions of Ovol1 were in the range of 47–600 nM) and  20 fmol ( 3 × 10
4 
cpm) of gel-puriﬁ  ed, 5′ 
32P end-labeled double-stranded oligonucleotides. 
Typically, binding reactions were performed in a 20-μl volume containing 
20 mM Hepes, pH 7.9, 75 mM KCl, 2.5 mM MgCl2, 2 mM DTT, 1 mM 
EDTA, 12% glycerol, and 1 μg of poly(dI-dC) for 30 min at room tempera-
ture. In competition experiments, a 100-fold molar excess of unlabeled 
competitor was used. The protein–DNA complexes were resolved on 6% 
nondenaturing polyacrylamide gels and visualized by autoradiography.
Reporter assays
UG1 keratinocytes were cultured and transfected as previously described 
(Li et al., 2002). 293T cells were seeded in 24-well plates and transfected 
at 12–15% conﬂ   uence with calcium phosphate as described previously 
(Pear et al., 1993). A typical transfection mixture contained a total of 
0.5 μg of plasmids, including 0.05 μg of a promoter construct (pGL3–
c-myc, in which a 2.3-kb human c-myc promoter fragment [a gift from 
G. Radziwill, University of Zurich, Zurich, Switzerland] drives the luciferase 
reporter [Hay et al., 1987], or pGL3-loricrin, in which a 1.3-kb mouse lo-
ricrin promoter fragment encompassing both the upstream and downstream 
transcription start sites drives the luciferase reporter [DiSepio et al., 1995]), 
with varying amounts of pCB6-Ovol1, an Ovol1 expression vector (Dai 
et al., 1998), and 0.04 μg of a β-actin–β- galactosidase construct or a 
total of 0.5 μg of plasmids, including 10 ng of a promoter construct with 
varying amounts of the VP16-Ovol1–expressing vector and 0.04 μg of 
a  β-actin promoter–β-galactosidase construct. pCB-6 (+) (empty vector 
containing the cytomegalovirus promoter) was used as stuffer DNA. Lucif-
erase activity was measured in whole cell extracts using the Luciferase 
Assay System (Promega), and β-galactosidase activity was measured as 
previously described (Eustice et al., 1991). For transfecting primary kerati-
nocytes, cells isolated from each newborn were plated in two 35-mm 
plates, one of which was treated with CaCl2 (ﬁ  nal concentration of 1.2 mM) 
24 h after plating. 3 h after calcium addition, each plate was transfected 
with 700 ng pGL3–c-myc and 350 ng β-actin–β-galactosidase using the 
helium-driven gene gun system (Biolistic PDS-1000; Bio-Rad Laboratories). 
Cells were collected 24 h later, luciferase activity was measured using the 
Luciferase Assay System (Promega), and β-galactosidase activity was mea-
sured using the Galacto-Light system (Tropix).
ChIP assays
293T cells (a human kidney epithelial cell line) were seeded in 10-cm 
plates, and each plate was transfected with 6 μg pCB6-Ovol1. PCR am-
pliﬁ  cation of the chromatin immunoprecipitates, prepared using the ChIP 
Assay Kit (Upstate Biotechnology) and anti-Ovol1 antibody (Dai et al., 
1998) according to the manufacturer’s instructions, was performed using 
the following primers containing sequences of the human c-myc promoter: 
1F, 5′-A  A  G  G  A  A  C  C  G  C  C  T  G  T  C  C  T  T  C  C  -3′; 1R, 5′-G  C  A  A  C  C  A  A  T  C  G  C  T  A  T  G-
C  T  G  G  A  -3′; 2F, 5′-G  G  G  A  A  A  G  A  G  G  A  C  C  T  G  G  A  A  A  G  G  -3′; 2R, 5′-A  G  A  G  A-
C  A  A  A  T  C  C  C  C  T  T  T  G  C  G  C  -3′; 3F, 5′-A  T  C  C  A  A  T  C  C  A  G  A  T  A  G  C  T  G  T  G  C  -3′; 
3R, 5′-A  A  G  A  A  G  G  G  T A T  T A  A T  G  G  G  C  G  C  -3′; 4F, 5′-A  T  C  C  T  C  T  C  T  C  G  C  T A  A T  C  T  C-
C  G  -3′; 4R, 5′-T  A  T  T  C  G  C  T  C  C  G  G  A  T  C  T  C  C  C  T  T  -3′; 5F, 5′-C  C  G  C  C  T  G  C  G  A  T-
G  A  T  T  T  A  T  A  C  T  -3′; and 5R, 5′-T  T  C  T  T  T  T  C  C  C  C  C  A  C  G  C  C  C  T  -3′. The following 
PCR program was used: 94°C for 1 min followed by 30 cycles of 94°C for 
45 s, 60°C for 45 s, and 72°C for 1 min followed by a ﬁ  nal extension at 
72°C for 7 min. The percent input value was calculated for each speciﬁ  c 
primer set as follows: (PCR band intensity from anti-Ovol1 immunoprecipi-
tate – PCR band intensity in IgG sample)/PCR band intensity from the input 
sample before immunoprecipitation.
Northern blot analysis, in situ hybridizations, and RT-PCR
Total RNA was extracted from embryonic skin, and Northern analysis 
was performed as described previously (Dai et al., 1998) using the fol-
lowing cDNA probes: a 304-bp fragment containing sequences corre-
sponding to 222–535 (5′-UTR) of c-myc mRNA (GenBank/EMBL/DDBJ 
accession no. X01023) and a 407-bp fragment containing sequences 
corresponding to 1,062–1,468 of Id2 mRNA (GenBank/EMBL/DDBJ ac-
cession no. AF077860; a gift from S. Sinha, State University of New 
York at Buffalo, Buffalo, NY). In situ hybridizations were performed as 
described previously (Dai et al., 1998) using digoxigenin-labeled anti-
sense and sense cRNA probes synthesized from a c-myc EST clone (Invit-
rogen). For RT-PCR, 5 μg RNA was reverse transcribed into cDNA using 
Superscript II RNase H reverse transcriptase (Invitrogen). PCR reactions 
were performed using the following primer set for loricrin: 5′-G  T  T  C  C  T  A  T-
G  G  A  G  G  T  G  G  T  T  C  C  A  G  C  T  G  -3′ and 5′-T  C  C  G  T  A  G  C  T  C  T  G  G  C  A  C  T  G  A  T  A  C  T-
G  T  -3′. For real-time PCR analysis, total RNA was extracted from primary 
keratinocytes cultured under low Ca
2+ conditions or treated for 24 h with 
CaCl2 (ﬁ   nal concentration of 1.2 mM) and reversed transcribed into 
cDNA. PCR reactions were set up using the iQ SYBR Green Supermix 
(Bio-Rad Laboratories) and gene-speciﬁ  c primer pairs for c-myc (F: C  T  C  G-
C  T  C  T  C  C  A  T  C  C  T  A  T  G  ; R: C  A  A  G  T  A  A  C  T  C  G  G  T  C  A  T  C  A  T  C  ) and glyceral-
dehyde-3-phosphate dehydrogenase (F: C  C  T  G  C  C  A  A  G  T  A  T  G  A  T  G  A  C  ; 
R: G  G  A  G  T  T  G  C  T  G  T  T  G  A  A  G  T  C  ). Reactions were completed on a real-time 
PCR machine (iCycler; Bio-Rad Laboratories) according to the manu-
facturer’s recommendations.
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